Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...

ITM announces positive Phase 3 results for ITM-11 in neuroendocrine tumours, paving the way for a potential new treatment ...

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...

Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

UCLA Health’s Outpatient Theranostics Center allows clinicians to treat up to 16 patients per day with Pluvicto and other ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

Some people use Zollinger-Ellison syndrome and gastrinoma interchangeably. Learn the similarities and differences between the ...